Russell Investments Group, Ltd. Hutchmed (China) LTD Transaction History

Russell Investments Group, Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$12.08 - $18.56 $90,781 - $139,478	7,515 Added 70.47%	18,179 $305,000
Q3 2023 Nov 13, 2023	BUY	$11.85 - $16.95 $126,368 - $180,754	10,664 New	10,664 $180,000
Q2 2022 Jul 29, 2022	SELL	$8.59 - $20.77 $60,069 - $145,244	-6,993 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$35.66 - $42.94 $78,202 - $94,167	2,193 Added 45.69%	6,993 $254,000
Q2 2021 Aug 04, 2021	SELL	$23.7 - $39.27 $130,776 - $216,691	-5,518 Reduced 53.48%	4,800 $159,000
Q1 2021 May 10, 2021	BUY	$27.01 - $36.8 $102,638 - $139,840	3,800 Added 58.3%	10,318 $289,000
Q4 2020 Feb 08, 2021	BUY	$27.51 - $34.36 $96,780 - $120,878	3,518 Added 117.27%	6,518 $204,000
Q2 2019 Aug 09, 2019	BUY	$22.0 - $31.78 $66,000 - $95,340	3,000 New	3,000 $91,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.